natgillin/translations-raw huggingface dataset:
This proportion is approximately 3-fold higher than the non- protein-bound (free) fraction of efavirenz in plasma.
Ta delež je približno 3-krat višji od frakcije efavirenza v plazmi, ki ni vezana na beljakovine (prosta frakcija).
This proportion tends to remain stable over prolonged periods of follow–up.
Po daljšem obdobju spremljanja ta delež stremi k stalni vrednosti.
This protein attaches to cholesterol receptors on the surface of liver cells and causes these receptors to be absorbed and broken down inside the cells.
Ta beljakovina se na površini jetrnih celic veže na receptorje za holesterol, zaradi česar se ti v celicah absorbirajo in razgradijo.
This protein is found at high levels in patients with the diseases that Benepali is used to treat.
Ta beljakovina je prisotna v visokih koncentracijah pri bolnikih z boleznimi, ki se zdravijo z zdravilom Benepali.
This protein is involved in inflammatory processes of the body and blocking it can reduce the inflammation in your body.
Ta beljakovina sodeluje v procesu vnetja in z njenim zaviranjem se lahko zmanjša vnetje v vašem telesu.
This protein is involved in inflammatory processes of the body and blocking it can reduce the inflammation in your body.
Ta beljakovina sodeluje v procesu vnetja in z njeno blokado se lahko zmanjša vnetje v vašem telesu.
This protein is located within the liver and the gut cells, where it is involved in assembling fatty substances into larger particles that are then released into the blood stream.
Ta protein je v jetrih in celicah črevesa, kjer je vključen v sestavljanje maščobnih snovi v večje dele, ki se nato sprostijo v krvni obtok.
This protein is normally involved in the absorption of fats from the diet.
Ta beljakovina običajno sodeluje pri absorpciji maščob iz hrane.
This protein stimulates the patient’s immune system (the body’s natural defences) to recognise and destroy melanoma cells.
Ta beljakovina spodbuja bolnikov imunski sistem (naravno obrambo telesa), da prepozna in uniči celice melanoma.
This provides a usable amount to deliver a single dose of 0.05 ml containing 0.5 mg ranibizumab.
Ta količina zadošča za injiciranje enkratnega odmerka 0,05 ml, ki vsebuje 0,5 mg ranibizumaba.
This radiopharmaceutical will deliver low amounts of ionising radiation associated with the least risk of cancer and hereditary abnormalities.
Ta radiofarmak bo dovajalo majhne količine ionizirajočega sevanja, povezanega z najmanjšim tveganjem za raka in prirojene nepravilnosti.
This rapidly stops dabigatran’s anticlotting effect.
Tako se protistrjevalni učinek dabigatrana hitro zaustavi.
This rare side effect may affect up to 1 in 1000 people treated with Hycamtin).
Ti redki neželeni učinki se lahko pojavijo pri največ 1 od 1.000 bolnikov, ki se zdravijo z zdravilom Hycamtin:
This rare side effect may affect up to 1 in 1000 people treated with Hycamtin):
Ti redki neželeni učinki se lahko pojavijo pri največ 1 od 1.000 bolnikov, ki se zdravijo z zdravilom Hycamtin:
This rarity also made the conduct of controlled clinical studies impossible.
Redkost bolezni tudi onemogoča izvedbo nadzorovanih kliničnih študij.
This reaction is reduced after subsequent injections.
Po nadaljnjih injekcijah je ta reakcija blažja.
This recurrence of the HSR is usually more severe than on initial presentation, and may include life- threatening hypotension and death.
Pri takšni ponovitvi je bila HSR običajno hujša kot pri prvem pojavu in je lahko vključevala življenjsko nevarno hipotenzijo in smrt.
This recurrence of the HSR is usually more severe than on initial presentation, and may include life- threatening hypotension and death.
Ta ponovitev preobčutljivostne reakcije je navadno hujša kot prvi pojav in lahko povzroči življenjsko nevaren padec krvnega tlaka in smrt.
This reduces inflammation, and the nerve damage caused by MS.
To zmanjšuje vnetje in poškodbe živčevja zaradi multiple skleroze.
This reduces its negative effects on the heart and the gut, making it less likely to cause side effects.
S tem se zmanjšajo negativni učinki na srce in črevesje, zaradi česar se zmanjša verjetnost pojavljanja neželenih učinkov.
This reduces the activity of some of the nerve cells in the brain and spinal cord, reducing the release of other neurotransmitters that are involved in epilepsy and anxiety.
S tem se zmanjša dejavnost nekaterih živčnih celic v možganih in hrbtenjači, zaradi česar se zmanjša sproščanje drugih živčnih prenašalcev, ki so povezani z epilepsijo in tesnobo.
This reduces the chances of an epileptic fit.
S tem se zmanjša možnost pojava epileptičnega napada.
This reduces the likelihood of a seizure occurring.
S tem se zmanjša verjetnost nastopa napada.
This reduces the loss of bone and maintains bone strength, making fractures less likely to happen.
S tem se zmanjša izguba kostne mase in ohrani jakost kosti, zaradi česar so zlomi manj verjetni.
This reduces the loss of bone, making fractures and other serious bone complications less likely to happen.
Zaradi tega je izguba kostne mase manjša, zlomi in drugi hudi zapleti z okostjem pa manj verjetni.
This reduces the risk of contamination, infection, leakage of insulin, blocked needles and inaccurate dosing.
Tako lahko zmanjšate tveganje za kontaminacijo, okužbo, iztekanje insulina, zamašitev igel in nepravilno odmerjanje.
This reduces the virus’s ability to
To zmanjšuje sposobnost
This reduction in body weight was seen in patients treated with prolonged-release exenatide irrespective of the occurrence of nausea although the reduction was larger in the group with nausea (mean reduction -2.9 kg to - 5.2 kg with nausea versus -2.2 kg to -2.9 kg without nausea).
To znižanje telesne mase pri bolnikih, ki so se zdravili z eksenatidom v obliki s podaljšanim sproščanjem, je bilo neodvisno od pojava navzee, bilo pa je večje pri skupini z navzeo (srednja vrednost znižanja -2,9 kg do -5,2 kg z navzeo proti -2,2 kg do -2,9 kg brez navzee).
This reduction in body weight was seen in patients treated with prolonged-release exenatide irrespective of the occurrence of nausea although the reduction was larger in the group with nausea (mean reduction -2.9 kg to -5.2 kg with nausea versus -2.2 kg to -2.9 kg without nausea).
To znižanje telesne mase pri bolnikih, ki so se zdravili z eksenatidom v obliki s podaljšanim sproščanjem, je bilo neodvisno od pojava navzee, bilo pa je večje pri skupini z navzeo (srednja vrednost znižanja -2,9 kg do -5,2 kg z navzeo proti -2,2 kg do -2,9 kg brez navzee).
This reduction in urinary CTx levels was significantly correlated with the primary efficacy endpoint SMPR (Kendall-tau-b (p<0.001)).
Znižanje koncentracij CTx v seču je bilo pomembno v korelaciji s primarnim ciljem raziskave učinkovitosti – stopnjo hitrosti obolevnosti okostja (Kendall-tau-b (p < 0,001)).
This regimen is an alternative recommended regimen for patients with genotype 4 infection, without cirrhosis or with compensated cirrhosis.
Ta režim je alternativni priporočeni režim zdravljenja pri bolnikih z okužbo z genotipom 4 brez ciroze ali s kompenzirano cirozo.
This regimen requires close monitoring (metabolic status, acid-base and electrolyte status, vital parameters etc.) in an intensive care unit or similar setting.
Takšna shema zahteva natančno kontrolo (presnovnega, acido-baznega in elektrolitskega ravnovesja, vitalnih parametrov idr.) v enoti za intenzivno nego ali podobnem okolju.
This regimen was administered every three weeks for 4 cycles in case at least a minor response (≥ 25 % reduction in bidimensionally measured tumour size) was observed after 2 cycles.
To terapevtsko shemo so uporabljali vsake tri tedne za 4 cikle, če so po 2 ciklih opazili vsaj manjši odziv (> 25 % zmanjšanje dvodimenzionalno merjene velikosti tumorja).
This regimen was administered every three weeks for 4 cycles in case at least a minor response (≥ 25% reduction in bidimensionally measured tumour size) was observed after 2 cycles.
Ta režim so uporabljali 4 cikle vsake 3 tedne, če so po 2 ciklih opazili vsaj majhen odziv (≥ 25 % zmanjšanje dvodimenzionalno merjene velikosti tumorja).
This regimen was administered every three weeks for 4 cycles in case at least a minor response (≥25% reduction in bidimensionally measured tumour size) was observed after 2 cycles.
To terapevtsko shemo so uporabljali vsake tri tedne za 4 cikle, če so po 2 ciklih opazili vsaj manjši odziv (≥ 25 % zmanjšanje dvodimenzionalno merjene velikosti tumorja).
This relationship is supported after reviewing the cases in Eudravigilance by the following: compatible temporal association; positive dechallenge in all cases with spontaneous recovery after withdrawal of apremilast and lack of confounding factors (concomitant medication, medical conditions).
To povezavo podpira pregled primerov v bazi Eudravigilance z naslednjim: združljiva časovna povezava; delno ali popolno izginotje neželenega učinka v vseh primerih s spontanim okrevanjem po ukinitvi apremilasta in odsotnost zavajajočih dejavnikov (sočasno zdravljenje, zdravstveno stanje).
This relative risk is not dependent on age or on duration of use, but as the baseline risk is strongly age-dependent, the overall risk of stroke in women who use oestrogen therapy will increase with age (see section 4.4).
To relativno tveganje ni odvisno od trajanja uporabe, vendar je izhodiščno tveganje močno odvisno od starosti, zato se skupno tveganje možganske kapi pri ženskah, ki uporabljajo zdravljenje samo z estrogenom, zveča s starostjo (glejte poglavje 4.4).
This removes the large air bubbles from the clear cartridge.
To odstrani velike zračne mehurčke iz prozornega vložka.
This represented an 84% median reduction in injection site pain.
To je predstavljalo 84 % mediano zmanjšanje bolečine na mestu injiciranja.
This represented an 84% median reduction in injection site pain.
To je predstavljalo 84% srednjega zmanjšanja bolečine na mestu injiciranja.
This represents a 25% reduction in the rate of severe asthma exacerbations for subjects treated with fluticasone furoate/vilanterol 92/22 micrograms compared with FF 92 (p=0.014).
To pomeni 25 % zmanjšanje deleža hudih poslabšanj astme pri preiskovancih, zdravljenih z flutikazonfuroatom/vilanterolom 92/22 mikrogramov, v primerjavi s prejemniki FF 92 mikrogramov (p = 0,014).
This resolves spontaneously within 48 hours without treatment.
To je brez zdravljenja spontano minilo v 48 urah.
This response to platinum medicines justified the use of the last platinum-based treatment.
Odziv na zdravila na osnovi platine je upravičil uporabo zadnjega zdravljenja na osnovi platine.
This response was maintained for up to 5 years.
Tak odziv se je ohranil do pet let.
This restriction of the indication of Raptiva is based on the present efficacy data and limited long-term experience with Raptiva.
Ta omejitev uporabe zdravila Raptiva temelji na dosedaj zbranih podatkih o učinkovitosti in omejenih izkušnjah z dolgotrajno uporabo zdravila Raptiva.
This result is similar to the reported values for factor VIII derived from human plasma.
Ti izsledki so bili v okviru vrednosti, o katerih so poročali za faktor VIII, pridobljenim iz humane plazme.
This result was confirmed in the follow-up PFS analysis (HR 0.85, 95% CI: 0.75 - 0.96; p = 0.0070) which included all events collected at the time of the final OS analysis.
Ta rezultat je bil potrjen v kontrolnih analizah PFS (RO 0,85, 95-odstotni IZ: 0,75–0,96; p = 0,0070), ki so vključevale vse dogodke, zbrane v času končne analize celokupnega preživetja.
This resulted in an average 39% decrease (maximum up to 80%) in midazolam plasma exposure after vemurafenib treatment.
Posledično se je izpostavljenost midazolamu v plazmi po zdravljenju z vemurafenibom zmanjšala za povprečno 39 % (in največ do 80 %).
This resulted in exaggerated pharmacological effects considered related to the compound's inhibition of skeletal calcium mobilisation, resulting in periparturient hypocalcaemia, a bisphosphonate class effect, dystocia and early termination of the study.
Prišlo je do poudarjenega farmakološkega delovanja, domnevno zaradi zaviranja mobilizacije kalcija v kosteh, ki je v obdobju okrog poroda povzročalo hipokalciemijo, kar je značilno za celotno skupino difosfonatov, distocijo in predčasno prekinitev študije.
This resulted in exaggerated pharmacological effects considered to be related to the compound’s inhibition of skeletal calcium metabolisation, resulting in periparturient hypocalcaemia, a bisphosphonate class effect, dystocia and early termination of the study.
Prišlo je do poudarjenega farmakološkega delovanja, domnevno zaradi zaviranja mobilizacije kalcija iz kosti, ki je v obdobju okrog poroda povzročalo hipokalciemijo (kar je značilno za celotno skupino difosfonatov), distocijo in predčasno prekinitev študije.
This resulted in exaggerated pharmacological effects considered to be related to the compound’s inhibition of skeletal calcium metabolisation, resulting in periparturient hypocalcaemia, a bisphosphonate class effect, dystocia and early termination of the study.
Prišlo je do poudarjenega farmakološkega delovanja, domnevno zaradi zaviranja mobilizacijekalcija iz kosti, ki je v obdobju okrog poroda povzročalo hipokalciemijo (kar je značilno za celotno skupino difosfonatov), distocijo in predčasno prekinitev študije.
This resulted in exaggerated pharmacological effects considered to be related to the compound’s inhibition of skeletal calcium metabolisation, resulting in periparturient hypocalcaemia, a bisphosphonate class effect, dystocia and early termination of the study.
Prišlo je do poudarjenega farmakološkega delovanja, domnevno zaradi zaviranja presnove kalcija v kosteh; to je povzročilo peripartalno hipokalciemijo, kar je učinek difosfonatov kot skupine, distocijo in predčasno prekinitev študije.
This resulted in exaggerated pharmacological effects considered to be related to the compound’s inhibition of skeletal calcium metabolism, resulting in periparturient hypocalcaemia, a bisphosphonate class effect, dystocia and early termination of the study.
Prišlo je do poudarjenega farmakološkega delovanja, domnevno zaradi zaviranja presnove kalcija v kosteh, ki je v obdobju okrog poroda povzročalo hipokalciemijo (kar je značilno za celotno skupino difosfonatov), distocijo in predčasno prekinitev študije.
This resulted in similar time course and extent of absolute LDL- C lowering.
To je povzročilo podoben časovni potek in obseg absolutnega znižanja LDL-H.
This results in harmful effects such as swelling and tissue damage.
To povzroča škodljive učinke, na primer otekanje in okvare tkiv.
This results in increased blood glucose levels and associated clinical signs such as polyuria (increase in urine volume), polydipsia (increase in water intake) and weight loss.
Posledica so povišane ravni glukoze v krvi in s tem povezani klinični znaki, kot so poliurija (povečano izločanje urina), polidipsija (čezmerno pitje vode) in zmanjšanje telesne mase.
This results in part from afamelanotide’s resistance to immediate degradation by serum or proteolytic enzymes (half-life approximately 30 min).
To je delno posledica odpornosti afamelanotida proti takojšnji razgradnji s serumskimi ali proteolitskimi encimi (razpolovni čas približno 30 min).
This results in the conversion of prothrombin into large amounts of thrombin independently of tissue factor.
Posledica je pretvorba protrombina v veliko količino trombina, neodvisno od tkivnega faktorja.
This results in the growth of cancer cells being reduced, while normal cells are only slightly affected.
Tako se zmanjša rast rakavih celic, medtem ko je vpliv na normalne celice zelo majhen.
This results in uncontrolled activity of the nervous system and the paralysis and death of the fleas and ticks.
S tem povzroči nenadzorovano delovanje živčnega sistema ter paralizo in smrt bolh in klopov.
This revaccination results in immunity to equine influenza lasting at least 12 months.
Revakcinacija vzbudi imunost proti influenci konj, ki traja najmanj 12 mesecev.
This risk is increased in subjects who are already immunosuppressed by their underlying disease.
To tveganje je večje pri osebah, ki so že imunsko oslabljene zaradi obstoječe bolezni.
This risk should be weighed against the disease characteristics of the child, such as evidence of disease progression (notably fibrosis), co-morbidities that may negatively influence the disease progression (such as HIV co-infection), as well as prognostic factors of response (HCV genotype and viral load).
To tveganje je treba pretehtati glede na značilnosti bolezni pri otroku, na primer glede na znake napredovanja bolezni (opazna fibroza), druge sočasne bolezni, ki bi lahko negativno vplivale na napredovanje bolezni (npr. sočasna okužba z virusom HIV) in prognostični dejavniki odziva na zdravljenje (genotip HCV in virusno breme).
This risk should be weighed against the disease characteristics of the child, such as evidence of disease progression (notably fibrosis), co-morbidities that may negatively influence the disease progression (such as HIV co-infection), as well as prognostic factors of response (HCV genotype and viral load).
To tveganje je treba pretehtati glede na značilnosti bolezni pri otroku, na primer glede na znake napredovanja bolezni (predvsem fibrozo), druge sočasne bolezni, ki bi lahko negativno vplivale na napredovanje bolezni (npr. sočasno okužbo s HIV), pa tudi prognostične dejavnike odziva na zdravljenje (genotip HCV in virusno breme).
This risk should be weighed against the disease characteristics of the child, such as evidence of disease progression (notably fibrosis), co-morbidities that may negatively influence the disease progression (such as HIV-co-infection), as well as prognostic factors of response (HCV genotype and viral load).
To tveganje je treba pretehtati glede na značilnosti bolezni pri otroku, na primer glede na znake napredovanja bolezni (predvsem fibrozo), druge sočasne bolezni, ki bi lahko negativno vplivale na napredovanje bolezni (npr. sočasno okužbo s HIV), pa tudi prognostične dejavnike odziva na zdravljenje (genotip HCV in virusno breme).
This scale must not be used to set the insulin dose.
Tega merila ne smete uporabljati za nastavljanje odmerka insulina.
This scale must not be used to set the insulin dose.
Tega merila se ne sme uporabljati za nastavljanje odmerka insulina.
This scan, along with other brain function tests, can help your doctor determine whether or not you may have β-amyloid plaques in your brain. β-Amyloid plaques are deposits sometimes present in the brains of people with dementias (such as Alzheimer’s disease).
Ta posnetek, lahko skupaj z drugimi testi delovanja možganov vašemu zdravniku pomaga ugotoviti, ali imate v možganih β-amiloidne lehe. β-amiloidne lehe so depoziti, ki včasih prisotni v možganih oseb z demencami (kot je Alzheimerjeva bolezen).
This scanner will enable the doctor to see inside the body to check for changes in the brain or spinal cord linked to MS or the brain infection called progressive multifocal leukoencephalopathy (PML) which has been associated with Tysabri and other MS medicines.
Ta naprava zdravniku omogoča, da spremlja spremembe v možganih ali hrbtenjači, povezane z multiplo sklerozo, in opazi okužbo možganov, imenovano progresivna multifokalna levkoencefalopatija (PML), ki je povezana z zdravilom Tysabri in drugimi zdravili za zdravljenje multiple skleroze.
This second part of the study showed that the average number of bleeding events in patients on preventive treatment was reduced to 1 to 6 events, compared with 18 to 82 events experienced by these patients during the year before the start of the preventive treatment.
V tem drugem delu študije se je povprečno število epizod krvavitev pri bolnikih, ki so prejemali preventivno zdravljenje, zmanjšalo na enega do šest dogodkov v primerjavi z 18 do 82 dogodki, ki so jih ti bolniki imeli v letu dni pred začetkom preventivnega zdravljenja.
This section contains information on how to give yourself an injection of Accofil.
To poglavje vsebuje podatke o tem, kako si sami injicirate zdravilo Accofil.
This section contains information on how to give yourself an injection of Aranesp.
To poglavje obsega informacije o tem, kako si sami injicirate zdravilo Aranesp.
This section contains information on how to give yourself an injection of Dynepo.
V naslednjih navodilih je razloženo, kako si sami injicirate zdravilo Dynepo.
This section contains information on how to give yourself an injection of Epoetin alfa HEXAL.
To poglavje vsebuje navodila za to, kako morate sami sebi dajati injekcije zdravila Epoetin alfa HEXAL.
This section contains information on how to give yourself an injection of Filgrastim HEXAL.
To poglavje vsebuje navodila za to, kako morate sami sebi dajati injekcije zdravila Filgrastim HEXAL.
This section contains information on how to give yourself an injection of Kineret.
To poglavje obsega informacije o tem, kako si sami injcirate zdravilo Kineret.
This section contains information on how to give yourself an injection of Nespo.
To poglavje obsega informacije o tem, kako si sami injicirate zdravilo Nespo.
This section contains information on how to give yourself an injection of Neupopeg.
To poglavje vsebuje informacije o tem, kako si sami injicirate zdravilo Neupopeg.
This section contains information on how to inject Herceptin.
Poglavje vsebuje informacije, kako injicirati zdravilo Herceptin.
This section contains information on how to properly use the Aranesp pre-filled pen.
To poglavje obsega informacije o pravilni uporabi napolnjenega injekcijskega peresnika zdravila Aranesp.
This section contains information on how to properly use the Neupopeg pre-filled pen.
To poglavje vsebuje informacije o tem, kako pravilno uporabiti napolnjeni injekcijski peresnik Neupopega.
This section contains information on how to use the Prolia pre-filled syringe.
To poglavje obsega informacije o uporabi napolnjene injekcijske brizge zdravila Prolia.
This section describes the clinical experience observed in three pivotal studies conducted with the Pandemic influenza vaccine H5N1 MedImmune in adults.
To poglavje opisuje klinične izkušnje v treh ključnih študijah s Cepivom proti pandemski gripi H5N1 MedImmune pri odraslih.
This section describes the clinical experience with the H5N1 mock-up vaccines following a two-dose administration of 7.5 microgram.
V tem poglavju so opisane klinične izkušnje z demonstracijskimi cepivi proti H5N1 po uporabi dveh odmerkov cepiva 7,5 mikrogramov.
This section describes the clinical experience with the mock-up vaccines following a two-dose administration.
To poglavje opisuje klinične izkušnje z modelnimi cepivi po uporabi dveh odmerkov.
This section describes the clinical experience with the mock-up vaccines.
V tem poglavju so navedene klinične izkušnje pri cepljenju z modelnimi (“mock-up”) cepivi.
This section includes only data derived from completed studies where patient exposure is known.
To poglavje vključuje le podatke, pridobljene iz dokončanih študij, pri katerih je izpostavljenost bolnic znana.
This section is divided into the following sub-sections:
To poglavje je razdeljeno na naslednja podpoglavja:
This section is divided into the following subsections:
To poglavje je razdeljeno v naslednja podpoglavja: Uvod
This section is divided into the following subsections: Introduction
To poglavje je razdeljeno v naslednja podpoglavja: Uvod
This section presents data from four randomised controlled trials in adults with rheumatoid arthritis, one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis, one study in adults with non-radiographic axial spondyloarthritis, four studies in adults with plaque psoriasis.
V tem poglavju so prikazani podatki iz štirih randomiziranih nadzorovanih preskušanj pri odraslih z revmatoidnim artritisom, ene študije pri odraslih s psoriatičnim artritisom, ene študije pri odraslih z ankilozirajočim spondilitisom, ene študije pri odraslih z radiografsko nezaznavnim aksialnim spondilartritisom, štirih študij pri odraslih s psoriazo v plakih.
This section provides information based on all adverse reactions from clinical trials, post-marketing studies or spontaneous reports.
To poglavje navaja informacije, ki temeljijo na vseh neželenih učinkih iz kliničnih preskušanj, postmarketinških študij in spontanih poročil.